. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Vascul Pharmacol. 2008 Apr 3;49(1):6–13. doi: 10.1016/j.vph.2008.03.005

Table 4.

Maximum contraction and estimated EC₅₀ values for ET-1 (10 pM – 100 nM) - induced contraction in thoracic vena cava from WT and sl/sl rats under control conditions, ET_A receptor blockade, ET_B receptor blockade and ET_A plus ET_B receptor blockade.

	Vena cava WT		Vena cava sl/sl

Treatment	Max contraction [% PE (10 μM)]	EC₅₀ (nM)	Max contraction [% NE (10 μM)]	EC₅₀ (nM)
Vehicle	414±76	16.98±4.24	452±76	10.82±2.93
Atrasentan (10 nM)	258±93 ^†	18.62±2.87 ^†	216±41^* ^†	22.30±5.48^*
BQ-788 (100 nM)	443±88	12.39±1.55	357±46	16.10±10.21
Atrasentan (10 nM) + BQ-788 (100 nM)	221±33^* ^†	29.12±4.83^* ^†	206±27^* ^†	18.20±3.08^*

Data are represented as mean ± S.E.M. Atrasentan, ET_A receptor antagonist; BQ-788, ET_B receptor antagonist; NE, norepinephrine; WT, homozygous wildtype rats; sl/sl, homozygous ET_B receptor deficient rats.

represents a statistically significant difference from control (p<0.05)

^†

represents a statistically significant difference from BQ-788 (p<0.05).